OnKure Therapeutics (OKUR) Accounts Payables (2020 - 2026)
OnKure Therapeutics' (OKUR) quarterly Accounts Payables came in at $11.0 million in Q1 2026, up 370.22% YoY from $2.3 million in Q1 2025, and up 669.16% on a QoQ basis from $1.4 million in Q4 2025.
OnKure Therapeutics (OKUR) Accounts Payables (2020 - 2026) Analysis & Trends
OnKure Therapeutics (OKUR) has 7 years of Accounts Payables data on file, last reported at $11.0 million in Q1 2026.
- Quarterly Accounts Payables rose 370.22% year-over-year to $11.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.0 million (up 370.22% YoY) and the FY2025 annual result came in at $1.4 million, down 51.72% from the prior year.
- Accounts Payables advanced to $11.0 million in Q1 2026, from $1.4 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $11.0 million in Q1 2026 to a low of $64000.0 in Q2 2024.
- A 5-year average of $2.3 million and a median of $1.8 million in 2023 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2024 — Accounts Payables tumbled 96.5% — and 2025, when it surged 3620.31%.
- Tracing OKUR's Accounts Payables over 5 years: stood at $1.9 million in 2022, then surged by 80.51% to $3.4 million in 2023, then declined by 13.14% to $3.0 million in 2024, then sank by 51.72% to $1.4 million in 2025, then surged by 669.16% to $11.0 million in 2026.
- The last three Accounts Payables figures came in at $11.0 million (Q1 2026), $1.4 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | OnKure Therapeutics | 196.98 Mn | 20.60 Mn | - | 2.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.00 Mn |
| Mar 31, 2026 | 11.02 Mn |
| Dec 31, 2025 | 1.43 Mn |
| Sep 30, 2025 | 1.29 Mn |
| Jun 30, 2025 | 2.38 Mn |
| Mar 31, 2025 | 2.34 Mn |
| Dec 31, 2024 | 2.97 Mn |
| Sep 30, 2024 | 237,000.00 |
| Jun 30, 2024 | 64,000.00 |
| Mar 31, 2024 | 676,000.00 |
| Dec 31, 2023 | 3.42 Mn |
| Sep 30, 2023 | 2.47 Mn |
| Jun 30, 2023 | 1.83 Mn |
| Mar 31, 2023 | 1.80 Mn |
| Dec 31, 2022 | 1.89 Mn |
| Sep 30, 2022 | 2.19 Mn |
| Jun 30, 2022 | 1.56 Mn |
| Mar 31, 2022 | 1.57 Mn |
| Dec 31, 2021 | 2.02 Mn |
| Sep 30, 2021 | 1.27 Mn |